Related Experiment Video
Updated: Aug 17, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Atrial fibrillation: current therapeutic approaches
1East Carolina University School of Medicine, Greenville, North Carolina.
Insights
Atrial fibrillation increases stroke risk. Anticoagulation is vital for chronic cases before and after cardioversion, while acute cases may not require it. Medical or electrical cardioversion can restore normal heart rhythm.
Area of Science:
- Cardiology
- Internal Medicine
- Pharmacology
Background:
- Atrial fibrillation (AF) poses a significant risk of life-threatening strokes.
- Anticoagulation therapy, including warfarin or aspirin, is crucial for managing embolic events in chronic AF patients with underlying heart conditions.
- Mitral valve stenosis is a common comorbidity associated with atrial fibrillation.
Purpose of the Study:
- To review the role of anticoagulation in atrial fibrillation management.
- To outline the timing and duration of anticoagulation therapy relative to cardioversion.
- To discuss current strategies for cardioversion in atrial fibrillation.
Main Methods:
- Literature review of anticoagulation and cardioversion strategies for atrial fibrillation.
- Analysis of treatment protocols for acute versus chronic atrial fibrillation.
- Evaluation of pharmacological (quinidine) and electrical cardioversion efficacy.
Main Results:
- Anticoagulation is recommended for chronic atrial fibrillation, starting three weeks before and continuing four weeks after cardioversion.
- Anticoagulation is generally not required before cardioversion in acute atrial fibrillation.
- Quinidine is a primary agent for medical cardioversion in stable patients; electrical cardioversion is effective for unstable patients or when drug therapy fails.
- Long-term antiarrhythmic therapy, such as quinidine, may be necessary to maintain sinus rhythm.
Conclusions:
- Anticoagulation management is critical for stroke prevention in atrial fibrillation patients undergoing cardioversion.
- Cardioversion strategies should be tailored based on the acuity of atrial fibrillation and patient stability.
- Maintaining sinus rhythm post-cardioversion often requires ongoing antiarrhythmic medication.
Abstract:
Atrial fibrillation is associated with potentially life-threatening strokes. Anticoagulation with warfarin or aspirin reduces the risk of embolic events in patients with chronic atrial fibrillation and mitral valve stenosis or other underlying heart disease. In patients with acute onset of atrial fibrillation, anticoagulation is not necessary before cardioversion. However, in patients with chronic atrial fibrillation, anticoagulation should be started three weeks before cardioversion and continued for four weeks after the return of normal sinus rhythm. Quinidine remains the agent most commonly used for medical cardioversion in patients who are hemodynamically stable. If a patient is hemodynamically unstable or the atrial fibrillation is not corrected with drug therapy, direct-current electrical cardioversion has a high success rate. Antiarrhythmic (quinidine) therapy is often continued indefinitely to help maintain sinus rhythm.
Related Concept Videos
Mitral Regurgitation III: Medical Management
Dysrhythmias VI: Management of Dysrhythmias
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Venous Thrombosis III: Interprofessional Care
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

